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Abstract: Zika virus (ZIKV) infection during pregnancy can cause devastating fetal neuropathological
abnormalities, including microcephaly. Most studies of ZIKV infection in pregnancy have focused
on post-implantation stage embryos. Currently, we have limited knowledge about how a preimplantation stage embryo deals with a viral infection. This study investigates ZIKV infection on
mouse trophoblast stem cells (TSCs) and their in vitro differentiated TSCs (DTSCs), which resemble
the cellular components of the trophectoderm layer of the blastocyst that later develops into the
placenta. We demonstrate that TSCs and DTSCs are permissive to ZIKV infection; however, ZIKV
propagated in TSCs and DTSCs exhibit substantially lower infectivity, as shown in vitro and in a
mouse model compared to ZIKV that was generated in Vero cells or mouse embryonic fibroblasts
(MEFs). We further show that the low infectivity of ZIKV propagated in TSCs and DTSCs is associated
with a reduced level of glycosylation on the viral envelope (E) proteins, which are essential for ZIKV
to establish initial attachment by binding to cell surface glycosaminoglycans (GAGs). The decreased
level of glycosylation on ZIKV E is, at least, partially due to the low-level expression of a glycosylationrelated gene, Hexa, in TSCs and DTSCs. Furthermore, this finding is not limited to ZIKV since similar
observations have been made as to the chikungunya virus (CHIKV) and West Nile virus (WNV)
propagated in TSCs and DTSCs. In conclusion, our results reveal a novel phenomenon suggesting
that murine TSCs and their differentiated cells may have adapted a cellular glycosylation system that
can limit viral infectivity by altering the glycosylation of viral envelope proteins, therefore serving as
a unique, innate anti-viral mechanism in the pre-implantation stage embryo.
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Zika virus (ZIKV) is a mosquito-borne Flavivirus belonging to the family Flaviviridae [1].
Other important human pathogenic viruses belonging to the same family include the
dengue virus (DENV), the West Nile virus (WNV), the yellow fever virus (YFV), the tickborne encephalitis virus (TBEV), and the Japanese encephalitis virus (JEV) [2]. ZIKV is
transmitted through day-biting mosquitoes, Aedes aegypti and Aedes albopictus. ZIKV was
first isolated in the Zika forest of Uganda in 1947. For a few decades, its infection in humans
only caused mild symptoms, including fever, headache, myalgia, arthralgia, rash, and
conjunctivitis, until the major outbreak in Brazil in 2015 [3]. During that outbreak, many
ZIKV infection cases were linked to severe neurological diseases that include intrauterine
growth restriction, congenital microcephaly, head growth deceleration in infants [4–6], and
Guillain-Barré syndrome (GBS) in adults [7].
The flaviviruses consist of a single-stranded, positive-sense RNA genome, which
encodes a polyprotein that is cleaved into three structural (capsid, pre-membrane, and
envelope) and seven non-structural proteins (NS1, NS2a, NS2b, NS3, NS4a, NS4b, and
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NS5) [2,8]. The flavivirus envelope (E) protein is a transmembrane glycoprotein that mediates cell surface receptor binding and endocytosis [2]. ZIKV and other flaviviruses make
initial contact with the host cell through E protein binding to glycosaminoglycans (GAGs),
such as heparan-sulfate proteoglycans or syndecans. GAGs are highly sulfated polysaccharides expressed on the cell surface and extracellular matrix of mammalian cells [9,10]. They
are prominently exposed on the cell surfaces of all tissues, providing an easily accessible
primary receptor for viral adhesion by electrostatic interactions [8]. It has been reported
that DENV, YFV, JEV, TBEV, Murray encephalitis virus, WNV, and chikungunya virus
(CHIKV) can use GAG receptors for the initial host cell attachment [11–14]. In addition,
the interaction of ZIKV E protein with different GAGs has also been reported [15], and
the level of glycosylation on E protein affects ZIKV attachment and infectivity [15,16].
Viral glycoproteins are glycosylated via post-translational modifications in the host cell. It
has been reported that viruses propagated in different host cells may compose different
glycosylation patterns on their glycoproteins, thus affecting virus–host attachment and
replication [17].
Trophoblasts are the first differentiated lineage that mediates blastocyst implantation
to the uterine epithelium [18]. TSCs are multipotent stem cells and primarily reside in the
polar trophectoderm region of the blastocyst that can differentiate into specialized subtypes of trophoblasts for placenta development [19]. TSCs can be induced to differentiate
into trophoblasts in vitro; therefore, they have been used as a model to study placental
development [2]. The placenta provides protection and nutrients to the developing embryo; however, its immune protective function to the fetus is not well-recognized [20].
Some viruses, including ZIKV, can cross the blood–placenta barrier, infect the fetus, and
cause devastating neuropathological abnormalities [21]. However, whether or to what
extent the trophectoderm in a blastocyst can offer immune protection is not clear. In this
study, we investigate ZIKV infection of mouse TSCs and their in vitro differentiated TSCs
(DTSCs). Our results reveal a novel phenomenon suggesting that murine TSCs and their
differentiated cells may have adapted a cellular glycosylation system that can limit viral
infectivity by altering the glycosylation of viral envelope proteins, therefore serving as a
unique, innate anti-viral mechanism in the pre-implantation stage embryo.
2. Methods and Materials
2.1. Ethics Statement and Biosafety
All animal care and experiments were conducted according to the Guide for the Care
and Use of Laboratory Animals under protocol #16031002, which was approved by the
Institutional Animal Care and Use Committee (IACUC) of The University of Southern
Mississippi (USM). All the experiments involving live ZIKV, CHIKV, and WNV were
performed by certified personnel in biosafety level 2 and 3 laboratories, following standard
biosafety protocols approved by the USM Institutional Biosafety Committee.
2.2. Viruses, Cells, and Animals
ZIKV (strain PRVABC59) was obtained from Dr. B. Johnson (CDC Arbovirus Branch,
Fort Collins, CO, USA), and CHIKV (LR OPY1 2006 strain) was provided by the University
of Texas Medical Branch. WNV (CT2741) was provided by Dr. John F. Anderson at the
Connecticut Agricultural Experiment Station. All viruses were propagated in Vero cells
(ATCC CCL-81), and the viral stocks were titrated in Vero cells by plaque assay as described
previously [22].
2.3. Cells
Vero cells were cultured in Dulbecco’s modified Eagle’s medium (DMEM, Life Technologies, Grand Island, NY, USA) containing 1% L-glutamine, 1% penicillin/streptomycin,
and 10% fetal bovine serum (FBS). Mouse TSCs were provided by Dr. Wei Hsu (University
of Rochester Medical Center) and cultured in RPMI 1640 containing 20% FBS, 1 mM sodium
pyruvate, 2 mM L-glutamine, 50 units/mL penicillin, 50 µg/mL streptomycin, 100 µM
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2-mercaptoethanol, 25 ng/mL FGF4, and 1 µg/mL heparin, with 70% of the medium preconditioned on mouse embryonic fibroblasts (MEFs). All cells were maintained at 37 ◦ C
in a humidified incubator with 5% CO2 . For the differentiation of TSCs, TSCs (50–60%
confluence) were cultured in unconditioned TSC basal medium without FGF4 and heparin
for 5–6 days. The differentiated cells, designated as DTSCs, were used for further studies
under the conditions specified in individual experiments. For the generation of MEFs,
male and female C57BL/6J mice were paired, and the appearance of the vaginal plug
was monitored the following morning. The presence of the vaginal plug was considered
as embryonic day 0.5 (E0.5). On E14.5, the pregnant female mice were sacrificed for the
collection and generation of MEFs, as previously described [23].
2.4. Mice
Breeding pairs of type I interferon receptor-deficient (Ifnar1−/− ) mice with a C57BL/6J
background were purchased from the Jackson Laboratory (Bar Harbor, ME, USA). The
breeders and the pups were housed under standard conditions in a clean room, and viral
infection studies were carried out in the BSL-3 animal facility at USM. Four-week-old
Ifnar1−/− mice were weighed and infected with 1 × 104 PFU of ZIKV generated in different
cells in 50 µL of PBS containing 1% FBS via footpad. Blood samples were collected on
days 2, 4, and 6 p.i. to measure the copy numbers of ZIKV by qPCR, and the viral burden
was expressed as log10 of PFU equivalent per ml of blood. Mice were observed daily for
survival up to day 30 p.i.
2.5. Attachment Assay
Cells were plated in 12-well plates at a density of 2 × 105 cells per well, incubated at
37
with 5% CO2 for 24 h. The cells were then infected with 1 MOI of different types of
ZIKV in cold (4 ◦ C) growth medium, and the plates were kept at 4 ◦ C for 1 h. After incubation, the wells were washed with cold PBS three times to remove the unattached viruses,
and the cells were collected in TRIreagent (Molecular Research Center, Inc., Cincinnati, OH,
USA) for total RNA isolation and qPCR quantification of ZIKV.
◦C

2.6. Plaque Assay
Vero cells were plated in 6-well plates at a density of 6 × 105 cells per well, incubated at
37 ◦ C with 5% CO2 for 24 h. Virus-containing media were added to the wells and incubated
at 37 ◦ C with 5% CO2 for 1 h. After incubation, the unattached virus was removed, and the
wells were covered with the first overlay medium and incubated at 37 ◦ C with 5% CO2
until the observation of plaques. The plaques were stained with Neutral Red, present in
the second overlay medium, then counted [22].
2.7. Quantitative PCR (qPCR)
Cells or mouse blood were collected for total RNA extraction with TRIreagent and
converted into first-strand cDNA using the iSCRIPTTM cDNA synthesis kit (Bio-Rad, Hercules, CA, USA). Probe-based (Bio-Rad) qPCR was performed using iTAQTM polymerase
supermix for the detection of ZIKV, CHIKV-E1, WNV E, and cellular β-actin, as described
previously [14,24–27]. For the relative quantification of Hexa (Forward: CGTCGCTGAGAGACTGTGGAG, Reverse: CCAGCTCACAACGGAAATGCG), SYBR Green-based
(Bio-Rad) qPCR was performed and normalized to cellular β-actin.
2.8. Heparin Sepharose Bead Binding Assay
Heparin-conjugated sepharose beads or heparin-unconjugated beads (60 µL) were
washed with DMEM, and 1 × 105 PFU of ZIKV in a volume of 60 µL was added to the
beads. The mixture was incubated at 4 ◦ C for 30 min to let the viruses attach to the beads.
The unattached viruses were removed by washing the beads three times with DMEM
containing 2% FBS. The bound viruses were lysed in 50 µL of Laemmli sample buffer (Alfa
Aesar, Haverhill, MA, USA), and the proteins were separated by SDS-polyacrylamide gel
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electrophoresis. The proteins were then transferred to a nitrocellulose membrane (Bio-Rad)
and blocked for 1 h with 5% bovine serum albumin at RT. Mouse monoclonal anti-flavivirus
primary antibody (4G2) was used to probe the membranes at 4 ◦ C overnight on a rocker.
After washing the membrane with Tris-buffered saline with Tween 20 (TBS-T), horseradish
peroxidase-conjugated goat anti-mouse IgG secondary antibody (Jackson Immunoresearch,
West Grove, PA, USA) was added for 1 h at RT. The membrane was washed with TBS-T and
developed using SuperSignal West Pico Chemiluminescent Substrate (Thermo Scientific,
Rockford, IL, USA) for acquiring the images using a ChemiDoc MP system (Bio-Rad).
2.9. Concentrating of ZIKV and Protein Glycosylation Assay
The culture media of ZIKVVero , ZIKVTSC , and ZIKVDTSC was centrifuged at 5000 rpm
for 5 min, and the supernatants were UV-inactivated. The viral particles were collected after
ultracentrifugation through 20% sucrose with 28,000 rpm at 4 ◦ C for 2 h (Beckman Coulter,
Brea, CA, USA). The viral proteins were de-glycosylated using peptide-N-glycosidase F
(PNGase F, Sigma, St. Louis, MO, USA) following the manufacturer’s instructions. ZIKV E
protein was probed with the 4G2 antibody in an immunoblotting assay, as above.
2.10. Immunoblotting Assay for HEXA
Vero cells transfected with Hexa siRNA were infected with 1 MOI of ZIKV. After 24 h,
the cells were collected and lysed in Laemmli sample buffer (Alfa Aesar, Haverhill, MA,
USA). The proteins were then separated by 10% SDS-polyacrylamide gel electrophoresis
and transferred to a nitrocellulose membrane (Bio-Rad) and blocked for 1 h with 5% bovine
serum albumin at RT. After treating with mouse-specific Rabbit primary antibody (HEXA,
Abcam, Boston, MA, USA) in the ratio 1:1000 at 4 ◦ C overnight on a rocker, the membrane
was washed with TBS-T. Horseradish peroxidase-conjugated secondary antibody (Goat
polyclonal Ab to Rabbit IgG, Abcam; 1:5000) was added for 1 h at RT; the membrane was
washed with TBS-T and developed using SuperSignal West Pico Chemiluminiscence Substrate (Thermo Scientific, Waltham, MA, USA) for acquiring the images using a ChemiDoc
MP system (Bio-Rad).
2.11. qPCR Array
MEFs and TSCs were plated in 12-well plates at a concentration of 2 × 105 cells per well.
After 24 h, the cells were collected, and total RNA was extracted with TRIreagent (Molecular
Research Center, Inc., Cincinnati, OH, USA) and converted into the first-strand cDNA using
an iSCRIPTTM cDNA synthesis kit (Bio-Rad). RT2 Profile PCR Array (Qiagen, Germantown,
MD, USA) was performed in a 96-well plate treated with SYBR Green-optimized primer
assays for mouse glycosylation-related genes following the manufacturer’s protocol.
2.12. Statistical Analyses
Data analysis was performed using Student’s t-test or analysis of variance (ANOVA)
in GraphPad Prism software (version 6.0), p < 0.05 being considered statistically significant.
3. Results
3.1. ZIKV Propagated in TSCs and DTSCs Exhibits Reduced Infectivity In Vitro
To test the infectivity of ZIKV in TSCs and DTSCs, we infected TSCs and DTSCs
with ZIKV and collected the cell media; ZIKVs propagated in these cells were named
ZIKVTSC and ZIKVDTSC , respectively. For comparative analysis, Vero cells were also
infected with ZIKV under the same condition, and the produced viruses were named
ZIKVVero . ZIKVVero developed plaques between 4–6 days in a plaque-forming assay,
whereas it took 7–10 days for ZIKVTSC and ZIKVDTSC to form plaques, indicating weak
infectivity of the viruses derived from TSCs and DTSCs. The infectivity of these viruses
was further examined by infecting Vero cells with a reverse-transcription quantitative
PCR (qPCR) assay. The results showed that the replication of ZIKVTSC and ZIKVDTSC
was approximately 20-fold and 100-fold lower than ZIKVVero at 24 h post-infection (p.i.),
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respectively (Figure 1A). As ZIKV is primarily transmitted by mosquitoes, we also assessed
the infectivity of ZIKVTSC and ZIKVDTSC in mosquito C6/36 cells. Similarly, we found
that the infectivity of ZIKVTSC and ZIKVDTSC was also significantly decreased compared
to ZIKVVero in C6/36 cells (Figure 1B). To confirm these qPCR results, we performed a
plaque-forming assay to measure the viral titers in the cell culture media. Consistently,
the results showed that ZIKVTSC and ZIKVDTSC decreased by approximately 100-fold the
infectious viral particles in both Vero and C6/36 cell cultures (Figure 1C,D). To test if the
reduced infectivity of ZIKVTSC and ZIKVDTSC may be due to reduced attachment to the
host cells, we incubated Vero cells with 1 MOI of ZIKV propagated in different cells at
4 ◦ C for 1 h. At this temperature, viruses can attach to the cells but cannot enter inside.
After incubation, the cells were washed with cold PBS to remove unbounded viruses, and
the attached viruses were quantified by qPCR. In comparison to ZIKVVero , the attachment
of ZIKVTSC and ZIKVDTSC was significantly lower (Figure 1E). Interestingly, ZIKVTSC
and ZIKVDTSC can regain their lost infectivity after re-propagation in Vero cells for one
additional passage (Figure 1F). These results suggest that ZIKV generated in TSCs and
DTSCs has lower attachment and infectivity, which may result from the different enzymatic
machinery in the host cells. To exclude the possibility that this phenomenon is due to the
origin of the Vero cells (African Green Monkey), we compared the infectivity of ZIKVTSC
and ZIKVDTSC with ZIKV generated in mouse embryonic fibroblasts (MEFs). The results of
viral RNA replication and the attachment assay also indicated that ZIKV-propagated TSCs
and DTSCs displayed reduced viral replication (Figure 1G) and attachment (Figure 1H).
We next tested if this phenomenon is only limited to ZIKV. For this, we propagated WNV
(another flavivirus) and CHIKV (an alphavirus) in TSCs, DTSCs, or Vero cells. Similarly,
our results demonstrated that both CHIKV (Figure 2A) and WNV (Figure 2B) propagated
in TSCs and DTSCs exhibited attenuated replication (Figure 2A,B) and attachment to the
host cells (Figure 2C,D) when compared to the viruses generated in Vero cells. These results
collectively demonstrate that ZIKV, WNV, and CHIKV propagated in TSCs and DTSCs
exhibit reduced infectivity in vitro, suggesting that an intrinsic deficiency in these stem
cells and their differentiated cells may attenuate these viruses.
3.2. ZIKVTSC and ZIKVDTSC Exhibit Attenuated Infectivity in Ifnar1−/− Mice
To evaluate the infectivity of ZIKVTSC and ZIKVDTSC in a mouse model, we infected
4-week-old type I Interferon receptor-deficient (Ifnar1−/− ) mice with 1 × 104 PFU of ZIKV
generated in different cells through footpad inoculation. Blood was collected on days (D)
2, 4, and 6 p.i., and the ZIKV E level was compared. Consistent with the in vitro results,
the ZIKV E levels in the blood of the mice inoculated with ZIKVTSC and ZIKVDTSC were
significantly lower than those infected with ZIKVVero on D2 p.i. With a similar trend, the
levels of viremia slowly increased in ZIKVTSC and ZIKVDTSC -infected mice at later time
points (Figure 3A). These ZIKV-infected mice were monitored daily for 30 days, and the
survival analysis shows that 35% of ZIKVVero -infected mice versus 100% of ZIKVTSC - and
ZIKVDTSC -infected mice survived (Figure 3B). In addition, we measured the weight loss of
the mice for 7 days before the mice started dying and found a trend that ZIKVVero -infected
mice lost more bodyweight than the mice infected with ZIKVTSC or ZIKVDTSC (Figure 3C).
These in vivo results indicate that ZIKVTSC and ZIKVDTSC have attenuated infectivity
in mice.
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Figure 1. ZIKV generated in TSCs and DTSCs decreases infectivity. Vero cells and C6/36 were infected with ZIKV (MOI = 1)
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3.3. ZIKVTSC and ZIKVDTSC Have Reduced Glycosylation on E Proteins
Like other flaviviruses, the attachment of ZIKV to the host cell receptors is mediated
by E protein. Although different cell surface receptors have been reported for ZIKV and
other flaviviruses, glycosaminoglycan (GAG) receptors play essential roles in flavivirus
infectivity. The binding of E protein to GAG receptors is the initial step in the attachment of
viruses to the cell surface, and the levels of glycosylation of E by the host cellular machinery
have been shown to affect the virus–host cell binding [28]. We thus hypothesized that
the lower binding ability of ZIKVTSC and ZIKVDTSC might be due to the deficiency in
glycosylation of TSCs and DTSCs. To test this, we pre-incubated Vero cells with different
concentrations of a soluble GAG, heparin, at 37 ◦ C for 1 h, then inoculated them with ZIKV
generated in TSCs and DTSCs (MOI = 1) at 4 ◦ C for 1 h for attachment analysis by qPCR.
The results showed that the pre-treatment of heparin reduced the attachment of ZIKVVero
to the cells in a concentration-dependent manner, whereas the attachment of ZIKVTSC and
ZIKVDTSC was promoted by heparin (Figure 4A). Consistent with the binding results, the
pre-treatment of Vero cells with heparin inhibited the replication of ZIKVVero but promoted
the replication of ZIKVTSC and ZIKVDTSC (Figure 4B). Interestingly, the pre-treatment
of ZIKV dramatically increased the binding of ZIKVTSC and ZIKVDTSC to Vero cells in
a heparin-concentration-dependent manner. In contrast, the pre-treatment of ZIKVVero
can also promote viral binding, which, however, did not further increase with heparin
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at concentrations above 200 U/mL (Figure 4C). To confirm these results, equal PFUs of
ZIKV grown in different cells were incubated with heparin-conjugated sepharose beads or
unconjugated control beads at 4 ◦ C for 30 min. After washing the unbound viruses, the
beads were collected for immunoblotting by probing the ZIKV E protein. Similar to the
qPCR results, we found that heparin inhibited the binding of ZIKVVero , but supported the
binding of ZIKVTSC and ZIKVDTSC (Figure 4D). To test if other GAGs have the same effect
7 of 18
as heparin, we tested the viral binding after the pre-treatment of Vero cells with
chondroitin
sulfate A (CSA). Like heparin, the CSA pre-treatment also inhibited the binding of ZIKVVero
but showed a trend to support the attachment of ZIKVTSC and ZIKVDTSC (Figure 4E). These
results suggest ZIKVTSC and ZIKVDTSC have a lower level of or incomplete glycosylation
in their E proteins, which may be due to a deficiency in the glycosylation machinery of
TSCs and DTSCs.

Figure 2. CHIKV and WNV generated in TSCs, and DTSCs decrease infectivity in vitro. Vero cells
were infected with 1 MOI of CHIKV (A) or WNV (B) that was generated in Vero, TSCs, or DTSCs. At
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Vero cells with genistein for 4 h and inoculated them with 1 MOI of ZIKVTSC , ZIKVDTSC , or
(Figure 3A). These ZIKV‐infected mice were monitored daily for 30 days, and the survival
ZIKVVero for the viral binding analysis by qPCR. The binding results showed that genistein
analysis shows
that 35% of ZIKVVero‐infected mice versus 100% of ZIKVTSC‐ and ZIKVDTSC‐
inhibited the attachment of ZIKVVero , but not ZIKVTSC and ZIKVDTSC (Figure 4G). To
infected mice survived (Figure 3B). In addition,
we measured the weight loss of the mice
for 7 days before the mice started dying and found a trend that ZIKVVero‐infected mice lost
more bodyweight than the mice infected with ZIKVTSC or ZIKVDTSC (Figure 3C). These in
vivo results indicate that ZIKVTSC and ZIKVDTSC have attenuated infectivity in mice.
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further confirm the hypothesis that the ZIKV particles generated in TSCs and DTSCs have
reduced glycosylation in their E proteins, we treated ZIKVTSC particles with PNGase F,
an enzyme that cleaves N-linked glycan from glycoproteins [31], and examined digested
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8 of 18
E protein fragments by immunoblotting. In ZIKV E, one conserved N-glycosylation site
has been reported at N154 [32]. As expected, we observed that a relatively smaller band
was produced in the ZIKVVero sample, but not in the ZIKVTSC sample, in the presence of
PNGase F, confirming our hypothesis that ZIKVTSC may have reduced glycosylation in
their E proteins (Figure 4H).

Figure 3. ZIKVTSC and ZIKVDTSC exhibit attenuated infectivity in Ifnar1−/− mice. Four-week-old Ifnar1−/− mice were
Figure
3. ZIKV
DTSC exhibit attenuated infectivity in Ifnar1−/− mice. Four‐week‐old Ifnar1−/− mice were infected
infected
with 1TSC×and
104 ZIKV
PFU of
ZIKVVero , ZIKVTSC , or ZIKVDTSC via footpad. (A) The ZIKV genome copies were quantified
with 1 × 104 PFU of ZIKVVero, ZIKVTSC, or ZIKVDTSC via footpad. (A) The ZIKV genome copies were quantified
by measuring
by measuring ZIKV with qPCR and expressed as log10 (PFU/mL). (B) The survival
curves of Ifnar1−/− mice infected
ZIKV with qPCR and expressed as log10 (PFU/mL). (B) The survival curves of Ifnar1−/− mice infected with the different
with the different strains of ZIKV. (C) Relative bodyweight changes of the mice compared to the weight before infection
strains of ZIKV. (C) Relative bodyweight changes of the mice compared to the weight before infection (Day 0). The data
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p < 0.01, and
and****
p < 0.0001,
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3.3. ZIKVTSC and ZIKVDTSC Have Reduced Glycosylation on E Proteins
3.4. The Expression of Hexa Was Decreased in TSCs and DTSCs
Like other flaviviruses, the attachment of ZIKV to the host cell receptors is mediated
To pin down which gene may be related to the deficiency in glycosylation in TSCs
by E protein. Although different cell surface receptors have been reported for ZIKV and
and DTSCs, we screened the expression of mouse glycosylation-related genes with a qPCR
other flaviviruses, glycosaminoglycan (GAG) receptors play essential roles in flavivirus
array. The array analysis showed that Hexa expression was downregulated 58-fold in TSCs
infectivity. The binding of E protein to GAG receptors is the initial step in the attachment
compared to the MEF control cells (Figure 5A). To confirm this result, we infected the MEFs,
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infection
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glycosylation
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TSCs
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DTSCs.
To
test
this,
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addition, there was the same trend of reduction of HEXA in TSCs and DTSCs as in Vero
concentrations
soluble
GAG,
at 37 °C for 1 h, analysis
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themThese
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(Figure 5C).
results
generated
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and
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=
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for
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for
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indicate that HEXA may contribute to the glycosylation of viral glycoproteins when the
The
results
showed
the pre‐treatment
of heparin reduced the attachment of ZIKVVero
viruses
replicate
in that
the host
cells.
to the cells in a concentration‐dependent manner, whereas the attachment of ZIKVTSC and
ZIKVDTSC was promoted by heparin (Figure 4A). Consistent with the binding results, the
pre‐treatment of Vero cells with heparin inhibited the replication of ZIKVVero but pro‐
moted the replication of ZIKVTSC and ZIKVDTSC (Figure 4B). Interestingly, the pre‐treat‐
ment of ZIKV dramatically increased the binding of ZIKVTSC and ZIKVDTSC to Vero cells
in a heparin‐concentration‐dependent manner. In contrast, the pre‐treatment of ZIKVVero
can also promote viral binding, which, however, did not further increase with heparin at
concentrations above 200 U/mL (Figure 4C). To confirm these results, equal PFUs of ZIKV
grown in different cells were incubated with heparin‐conjugated sepharose beads or un‐
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sulfate A (CSA). Like heparin, the CSA pre‐treatment also inhibited the binding of ZIK‐
VVero but showed a trend to support the attachment of ZIKVTSC and ZIKVDTSC (Figure 4E).
These results suggest ZIKVTSC and ZIKVDTSC have a lower level of or incomplete glycosyl‐
ation in their E proteins, which may be due to a deficiency in the glycosylation machinery
of TSCs and DTSCs.
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Figure 4. ZIKV grown in TSCs and DTSCs has reduced glycosylation. (A) Vero cells were pre-treated with heparin at
Figure 4. ZIKV grown in TSCs and DTSCs has reduced glycosylation. (A) Vero cells were pre‐treated with heparin at
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In summary, the inhibition and siRNA knockdown results demonstrate that host cell HEXA
plays an essential role in supporting ZIKV binding and replication, possibly through
enhancing E protein glycosylation.
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knockdown results demonstrate that host cell HEXA plays an essential role in supporting
ZIKV binding and replication, possibly through enhancing E protein glycosylation.
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Figure 6. HEXA contributes to the glycosylation of ZIKV during the replication in TSCs and DTSCs. (A) MEFs, TSCs, and
Figure
HEXA
contributes
the glycosylation
of concentrations
ZIKV during the
in TSCswith
andZIKV
DTSCs.
(A) MEFs,
DTSCs6.were
pre-treated
withtoZ-Pugnac
at different
forreplication
4 h, then infected
(1 MOI)
for 24TSCs,
h, andand
the
DTSCs
were
pre‐treated
with
Z‐Pugnac
at
different
concentrations
for
4
h,
then
infected
with
ZIKV
(1
MOI)
for
24
h,
and
viruses in the cells were quantified by qPCR. (B) Vero cells were infected with ZIKV generated in MEFs in the presence
the viruses in the cells were quantified by qPCR. (B) Vero cells were infected with ZIKV generated in MEFs in the presence
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4. Discussion
An early embryo is the most crucial stage in the life cycle of mammals, and it faces
dynamic immunological challenges during embryogenesis [20]. The blastocyst consists of
two major components: the inner cell mass (ICM) and the trophectoderm, which give rise
to the fetus and the placenta, respectively. A series of our recent studies have demonstrated
that embryonic stem cells (ESCs) derived from the ICM have an underdeveloped interferonmeditated anti-viral system [34]. This is a surprising finding since the IFN response is a
critical innate anti-viral immunity, presumably developed in most, if not all, cell types
in vertebrate animals [35]. Increasing evidence suggests that early embryos may have
adapted distinct anti-viral mechanisms that are different from a developed organism [34].
As part of our effort to characterize the immune properties of the early embryonic cells, this
study used multiple experimental approaches and demonstrated that the trophectoderm
may utilize glycosylation as a unique anti-viral strategy to protect the early embryo from
viral infection.
Congenital ZIKV infection has been associated with neuronal birth defects in newborns [36]. As ZIKV can cross the placenta and infect the fetus, it is plausible to hypothesize
that ZIKV may first infect TSCs and DTSCs, then the fetus. Interestingly, our results demonstrate that ZIKV generated in TSCs and DTSCs exhibit significantly lower infectivity in
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Vero cells, C6/36 cells, and mice. However, after passing a single passage of ZIKVTSC and
ZIKVDTSC on Vero cells, these viruses regained the lost infectivity, indicating some intrinsic
deficiencies related to post-translational modifications in TSCs and DTSCs (compared
with Vero cells) that mitigate ZIKV infectivity. In addition, this phenomenon remained
true when we compared the infectivity of ZIKV generated in TSCs and DTSCs with those
generated in MEFs. Further, the attenuation of infectivity was also noticed in CHIKV and
WNV after growing in TSCs and DTSCs.
The first step of a viral life cycle is the attachment to the host cell. Although a few
molecules have been shown to mediate ZIKV E binding to the host cells, a specific cellular
receptor for ZIKV is still not known [37]. Mammalian cell surface GAG receptors have been
reported to play a significant role in the initial attachment for different viruses [15,38–40].
Our previous study in CHIKV has shown that CHIKV propagated in C6/36 cells exhibited
a lower GAG-binding ability than those grown in Vero cells [14]. The interaction of ZIKV
E protein with different GAGs has also been reported [15], and the level of glycosylation
on E protein affects ZIKV attachment and infectivity [16]. Similarly, our GAG receptor
neutralization results with heparin showed that ZIKVTSC and ZIKVDTSC have reduced
binding to GAG receptors.
Viral proteins are glycosylated via post-translational modifications in the host cell. It
has been reported that viruses propagated in different host cells may compose different
glycosylation patterns on their glycoproteins, thus affecting virus–host attachment and
replication [17,41]. Enveloped viruses can acquire a portion of the host cell membrane as
their envelope via budding, which can cause differences in the carbohydrate and lipid
composition of the virus [42–44]. Further, different cell types use different enzymes for
the post-translational modification process during N-glycosylation to modify the viral
glycoproteins [45,46]. In addition, the carbohydrate residues at the glycosylation sites also
depend on the type of cells used to propagate the viruses. In this study, we have demonstrated that ZIKVTSC has a reduced level of glycosylation on E proteins by treatment with
PNGase F. The deficiency in glycosylation of ZIKVTSC and ZIKVDTSC was also confirmed
with the experiments of propagating ZIKV in Vero cells in the presence of Tunicamycin or
Genistein, both of which can inhibit the process of glycosylation of mammalian cells [30,47].
The presence of either Tunicamycin or Genistein in the cell culture of Vero cells significantly
reduces the infectivity and attachment of ZIKVVero , but not of ZIKVTSC or ZIKVDTSC . Besides E protein, PrM/M is another glycoprotein of flaviviruses. A recent study showed that
removing the N-glycosylation site from the prM or both prM and E in a ZIKV infectious
clone did not result in infectious ZIKV [48]. The absence of the N-glycan on prM or E
led to protein aggregation in the rough endoplasmic reticulum (ER) compartment, which
was more pronounced when N-glycan on prM was removed [48]. Although we did not
assess the level of glycosylation on the PrM/M of ZIKVTSC or ZIKVDTSC , it is possible that
attenuated infectivity is also contributed by the incomplete glycosylation of PrM/M, which
needs further investigation.
Glycosylation is an inducible and reversible post-translational modification of proteins [49]. A set of enzymes belonging to O-GlcNAc transferase (OGT) can transfer the
GlcNAc residue from UDP-GlcNAc to the serine or threonine residues of the target proteins [50,51]. Similarly, another set of O-GlcNAcase (OGA) enzymes can remove GlcNAc
from the proteins [52,53]. The level of glycosylation is sensitive to the nutrients in the
cellular environment, and the differences in the nutrient status, hormone levels, and extracellular environmental stress can change the level of GlcNAc in the proteins [54,55]. The
level of the OGT and OGA has been reported to be altered in stem cells [56–58]. In this study,
we found that the expression of one of the members of OGA, Hexa, is significantly reduced
in TSCs and DTSCs compared to MEFs and Vero cells. As OGA helps recycle GlcNAc to the
HBP pool through the salvage pathway [59], the decreased expression of Hexa can disturb
the glycosylation process. Further, studies have reported that the expression of OGT and
OGA is sensitive to fluctuations at cellular GlcNAc levels, and cells can coordinate their
expression to buffer themselves from drastic shifts in glycosylation [60–63]. Further, the
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mutation in Hexa has also been linked with a congenital disorder in humans, Tay Sachs
disease, in which the growth and development of the brain is inhibited [64]. In this study,
we inhibited the expression of Hexa in Vero cells by using Z-Pugnac or siRNA. In both cases,
ZIKV generated in Hexa-inhibited conditions decreased its infectivity, suggesting that Hexa
at least partially contributes to the glycosylation of ZIKV E protein, which is deficient
in mouse TSCs and DTSCs. It is worth noting that the expression of another member of
OGT (Wbscr17) was also downregulated in TSCs, albeit to a lesser extent compared to Hexa
(Figure 5A). It is possible that the reduced expression of Wbscr17 may also contribute to the
attenuation of ZIKV in stem cells, which needs further investigation.
In conclusion, this study has discovered a novel phenomenon that viruses generated
in TSCs and DTSCs, including ZIKV, WNV, and CHIKV, exhibit attenuated infectivity in
cultured cells and reduced pathogenicity in mice. Mechanistically, we have demonstrated
that this is partly due to the unique glycosylation system in TSCs and DTSCs that produces
Cells 2021, 10, x FOR PEER REVIEW
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a low level of viral protein glycosylation, thus limiting virus attachment to and invasion
of
host cells, as shown in Figure 7. Physiologically, we propose that this could be a unique,
innate anti-viral mechanism adapted by early embryos.
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